Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis
Study Details
Study Description
Brief Summary
Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- The consistency of drug sensitivity [3 years]
To test the consistency of drug sensitivity of primary tumor and its matched liver metastasis
Secondary Outcome Measures
- The establishment of PDO [3 years]
To test the rate of PDO derived from primary and matched metastatic colorectal cancer .
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically proven colorectal cancer with liver metastasis
-
Aged between 18 and 70 years
-
Written informed and signed consent
-
Accessible to surgery sample of metastasis and primary tumor
Exclusion Criteria:
-
Less than 18 years and older than 70 years
-
Not able to give informed consent
-
Not accessible to surgery sample
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Colorectal Surgery in Changhai Hospital | Shanghai | Shanghai | China | 200433 |
Sponsors and Collaborators
- Changhai Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHCS-PDO